Tower Research Capital (TRC)’s RxSight RXST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$25.9K Sell
4,197
-1,012
-19% -$8.4K ﹤0.01% 3298
2025
Q4
$54.3K Buy
5,209
+195
+4% +$1.96K ﹤0.01% 2355
2025
Q3
$45.1K Sell
5,014
-560
-10% -$4.92K ﹤0.01% 2610
2025
Q2
$72.5K Buy
5,574
+3,398
+156% +$51.1K ﹤0.01% 2650
2025
Q1
$54.9K Buy
2,176
+821
+61% +$24.4K ﹤0.01% 2168
2024
Q4
$46.6K Sell
1,355
-1,169
-46% -$52.7K ﹤0.01% 2603
2024
Q3
$125K Sell
2,524
-2,739
-52% -$140K ﹤0.01% 2059
2024
Q2
$317K Buy
5,263
+5,052
+2,394% +$289K 0.01% 1720
2024
Q1
$10.9K Sell
211
-1,263
-86% -$62K ﹤0.01% 3633
2023
Q4
$59.4K Sell
1,474
-1,572
-52% -$46.1K ﹤0.01% 3016
2023
Q3
$85K Buy
3,046
+2,703
+788% +$80.6K ﹤0.01% 2101
2023
Q2
$9.88K Sell
343
-220
-39% -$4.89K ﹤0.01% 4202
2023
Q1
$9K Sell
563
-168
-23% -$2.37K ﹤0.01% 4536
2022
Q4
$9K Sell
731
-444
-38% -$5.4K ﹤0.01% 4251
2022
Q3
$14K Buy
1,175
+171
+17% +$2.35K ﹤0.01% 4224
2022
Q2
$14K Sell
1,004
-24
-2% -$317 ﹤0.01% 4163
2022
Q1
$13K Sell
1,028
-982
-49% -$11.8K ﹤0.01% 3998
2021
Q4
$23K Buy
2,010
+1,333
+197% +$16K ﹤0.01% 3525
2021
Q3
$9K Buy
+677
New +$9.32K ﹤0.01% 4465

Other funds holding RXST

Tower Research Capital (TRC)'s RXST Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its RxSight (RXST) stake by 19% in Q1 2026, selling an estimated $8.4K and leaving 4,197 shares worth $25.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3298.

Tower Research Capital (TRC) first reported a position in RXST in Q3 2021 and has held it in 19 quarters since. The position peaked at $317K in Q2 2024. 164 funds tracked by Wall St. Rank hold RXST as of Q1 2026.

  • Tower Research Capital (TRC) held 4,197 shares of RxSight worth $25.9K as of Q1 2026.
  • Tower Research Capital (TRC) sold 1,012 RxSight shares in Q1 2026, an estimated $8.4K.
  • RxSight made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3298 holding.
  • Tower Research Capital (TRC) first reported a position in RxSight in Q3 2021 and has held it in 19 quarters since.
  • Tower Research Capital (TRC)'s RxSight position peaked at $317K in Q2 2024.
  • 164 funds tracked by Wall St. Rank held RxSight as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.